Kairos Pharma Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- Kairos Pharma Ltd.
- Ownership
- Public
- Status
- Active
- Ticker symbol
- KAPA
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001962011
Board of directors
-
Hansoo Michael Keyoung · DirectorSince 2024
-
Hyun W. Bae · DirectorSince 2024
-
John S. Yu · Director · CEO and ChairmanSince 2024
-
Rahul Singhvi · DirectorSince 2024
-
Rosemary Mazanet · DirectorSince 2024
Chief executives
John S. Yu
· CEO and Chairman
Since September 2024
Board connections
1 of this board's directors also sit on 1 other board.
- via Rahul Singhvi
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 8, 2025 | Bhowmick Neil Officer (Chief Scientific Officer) | Grant or award | +171,756 | — | — |
| Oct 8, 2025 | Murali Ramachandran Officer (VP of Research and Development) | Grant or award | +152,672 | — | — |
| Oct 8, 2025 | Rahul Singhvi Director | Grant or award | +19,084 | — | — |
| Oct 8, 2025 | Samuelson Doug Officer (Chief Financial Officer) | Grant or award | +152,672 | — | — |
| Oct 8, 2025 | John S. Yu Director, Officer (CEO and Chairman), 10% owner | Grant or award | +190,840 | — | — |
| Oct 8, 2025 | Hyun W. Bae Director | Grant or award | +19,084 | — | — |
| Oct 8, 2025 | Hansoo Michael Keyoung Director | Grant or award | +19,084 | — | — |
| Sep 16, 2025 | Hyun W. Bae Director | Grant or award | +10,000 | — | — |
| Sep 16, 2025 | Hansoo Michael Keyoung Director | Grant or award | +10,000 | — | — |
| Jan 1, 2025 | Murali Ramachandran Officer (VP of Research and Development) | Grant or award | +14,000 | — | — |
| Jan 1, 2025 | John S. Yu Director, Officer (CEO and Chairman), 10% owner | Grant or award | +14,000 | — | — |
| Jan 1, 2025 | Bhowmick Neil Officer (Chief Scientific Officer) | Grant or award | +14,000 | — | — |
| Nov 25, 2024 | Murali Ramachandran Officer (VP of Research and Development) | Open-market purchase | +200 | $1.59 | $318 |
| Nov 22, 2024 | Samuelson Doug Officer (Chief Financial Officer) | Open-market purchase | +2,500 | $1.50 | $3,750 |
| Nov 20, 2024 | John S. Yu Director, Officer (CEO and Chairman), 10% owner | Open-market purchase | +4,000 | $1.44 | $5,760 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.